Patricia S. Larrabee

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.

Michael R. Bristow, Wayne Minobe, R Rasmussen et al. · Journal of Clinical Investigation · 1992 · 318 citations · Full text

Cardiac Muscle, Hypertension, Heart Failure +17

Age-related changes in beta-adrenergic neuroeffector systems in the human heart.

Michel White, Robert L. Roden, Wayne Minobe et al. · Circulation · 1994 · 287 citations

Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.

Michael R. Bristow, Fred Anderson, J. David Port et al. · Circulation · 1991 · 253 citations · Full text